Ensysce Biosciences reports Q4 2025 net loss of $2.8M, advances PF614 Phase 3 trial

Ensysce Biosciences, Inc.

Cash $4.3M at Dec 31, 2025; net loss for 2025 $10.2M vs $8.0M in 2024.
R&D expenses rose $3.2M to $10.4M due to clinical programs for PF614 and PF614-MPAR.
Enrolled first patient in Phase 3 trial (PF614-301) for moderate-to-severe post-surgical pain.
FDA supports streamlined 505(b)(2) pathway for PF614-MPAR with overdose-protection labeling.
USPTO allowed new MPAR patent covering composition-of-matter and method-of-use claims through 2042.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Ensysce Biosciences, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 30, 2026, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2025.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-013622

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.